Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is Caligan Partners LP's 7th Largest Position

Caligan Partners LP grew its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 8.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 626,280 shares of the biopharmaceutical company's stock after acquiring an additional 46,563 shares during the quarter. Agios Pharmaceuticals comprises 5.5% of Caligan Partners LP's holdings, making the stock its 7th largest holding. Caligan Partners LP owned 1.10% of Agios Pharmaceuticals worth $20,580,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Venturi Wealth Management LLC bought a new stake in Agios Pharmaceuticals during the fourth quarter worth $33,000. Wingate Wealth Advisors Inc. bought a new stake in shares of Agios Pharmaceuticals in the 4th quarter worth $53,000. Sterling Capital Management LLC raised its holdings in shares of Agios Pharmaceuticals by 818.0% in the fourth quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock valued at $59,000 after purchasing an additional 1,587 shares during the last quarter. KBC Group NV lifted its position in shares of Agios Pharmaceuticals by 30.5% during the fourth quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock valued at $86,000 after purchasing an additional 611 shares in the last quarter. Finally, AlphaQuest LLC lifted its position in shares of Agios Pharmaceuticals by 106.2% during the fourth quarter. AlphaQuest LLC now owns 4,540 shares of the biopharmaceutical company's stock valued at $149,000 after purchasing an additional 2,338 shares in the last quarter.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. Scotiabank lowered their target price on Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating on the stock in a research note on Friday. HC Wainwright assumed coverage on shares of Agios Pharmaceuticals in a report on Monday, February 24th. They issued a "buy" rating and a $58.00 price target on the stock. Finally, StockNews.com raised shares of Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Thursday. Five research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, Agios Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $56.00.

Insider Buying and Selling

In other Agios Pharmaceuticals news, Director Jacqualyn A. Fouse sold 7,497 shares of the business's stock in a transaction dated Thursday, April 10th. The stock was sold at an average price of $25.90, for a total value of $194,172.30. Following the completion of the transaction, the director now owns 149,220 shares of the company's stock, valued at approximately $3,864,798. The trade was a 4.78 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.93% of the stock is owned by company insiders.

Agios Pharmaceuticals Price Performance

Agios Pharmaceuticals stock traded down $0.12 during trading hours on Monday, reaching $29.98. The stock had a trading volume of 358,625 shares, compared to its average volume of 699,503. The company has a fifty day simple moving average of $29.81 and a 200-day simple moving average of $37.76. The stock has a market cap of $1.74 billion, a PE ratio of 2.64 and a beta of 0.83. Agios Pharmaceuticals, Inc. has a 52 week low of $23.42 and a 52 week high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($1.55) EPS for the quarter, topping the consensus estimate of ($1.80) by $0.25. The business had revenue of $8.73 million during the quarter, compared to analyst estimates of $9.86 million. Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. Research analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.